Biomarkers: An Overview for Oncology Nurses

Seminars in Oncology Nursing

Volumn 28, Issue 2, 2012, Pages 87-92

  Richmond, Ellen S ^a   Dunn, Debra ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Biomarker; Biomarker validation; Genomics; Oncology nursing; Proteomics

Indexed keywords

TUMOR MARKER;

ARTICLE; GENOMICS; HUMAN; NEOPLASM; NURSING; ONCOLOGY NURSING; PERSONALIZED MEDICINE; PROTEOMICS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; ONCOLOGIC NURSING; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84860230934     PISSN: 07492081     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soncn.2012.03.002     Document Type: Article

References (37)

1. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95. NIH Working Group.
2. Smith J.J., Sorensen A.G., Thrall J.H. Biomarkers in imaging: realizing radiology's future. Radiology 2003, 227:633-638.
3. Diamandis E.P. Cancer biomarkers: can we turn recent failures into success?. J Natl Cancer Inst 2010, 102:1462-1467.
4. Sahu P., Pinkalwar N., Dubey R.D., et al. Biomarkers: an emerging tool for diagnosis of a disease and drug development. Asian J Res Pharm Sci 2011, 1:9-16.
5. Demshar R., Vanek R., Mazanec P. Oncologic emergencies: new decade, new perspectives. AACN Adv Crit Care 2011, 22:337-348.
6. Kantor S.M., Ossa K.S., Hoshaw-Woodard S.L., et al. Height loss and osteoporosis of the hip. J Clin Densitom 2004, 7:65-70.
7. Crick F. Molecular biology in the year 2000. Nature 1970, 228:613-615.
8. Chial H. Mendelian genetics: patterns of inheritance and single-gene disorders. Nature Education 2008, 1(1). Available at:. http://www.nature.com/scitable/topicpage/mendelian-genetics-patterns-of-inheritance-and-single-966.
9. Cochaux P., Velu T., Abramowicz M., et al. [Molecular and diagnostic genetics]. Revue medicale de Bruxelles 1990, 11:188-194.
10. Croce C.M. Oncogenes and cancer. N Engl J Med 2008, 358:502-511.
11. Dunn B., Jegalian K., Greenwald P. Biomarkers for early detection and surrogate endpoints in cancer prevention trials: issues and opportunites. Recent Results in Cancer Research #188: Clinical Cancer Prevention 2011, 21-40. Springer Verlag, Berlin. H.-J. Senn, F. Otto (Eds.).
12. Tyers M., Mann M. From genomics to proteomics. Nature 2003, 422:193-197.
13. Petricoin E.F., Zoon K.C., Kohn E.C., et al. Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov 2002, 1:683-695.
14. Luscombe N.M., Greenbaum D., Gerstein M. What is bioinformatics? A proposed definition and overview of the field. Methods Info Med 2001, 40:346-358.
15. Croswell J.M., Ransohoff D.F., Kramer B.S. Principles of cancer screening: lessons from history and study design issues. Semin Oncol 2010, 37:202-215.
16. Allison J.E., Tekawa I.S., Ransom L.J., et al. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996, 334:155-159.
17. Engstrom P.F., Bloom M.G., Demetri G.D., et al. NCCN molecular testing white paper: effectiveness, efficiency, and reimbursement. J Natl Compr Cancer Netw 2011, 9(suppl 6):S1-S16.
18. Teutsch S.M., Bradley L.A., Palomaki G.E., et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP working group. Genet Med 2009, 11:3-14.
19. Tolaney S.M., Winer E.P. Follow-up care of patients with breast cancer. Breast 2007, 16(suppl 2):S45-S50.
20. Kelloff G.J., Sigman C.C. New science-based endpoints to accelerate oncology drug development. Eur J Cancer 2005, 41:491-501.
21. McShane L.M., Hunsberger S., Adjei A.A. Effective incorporation of biomarkers into phase II trials. Clin Cancer Res 2009, 15:1898-1905.
22. Putti T.C., El-Rehim D.M., Rakha E.A., et al. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol 2005, 18:26-35.
23. Kumar P., Rehani M.M., Kumar L., et al. Tumor marker CA-125 as an evaluator and response indicator in ovarian cancer: its quantitative correlation with tumor volume. Med Sci Monit 2005, 11:CR84-CR89.
24. Korkaya H., Paulson A., Iovino F., et al. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 2008, 27:6120-6130.
25. Ezzeldin H.H., Diasio R.B. Genetic testing in cancer therapeutics. Clin Cancer Res 2006, 12:4137-4141.
26. Kishi S., Yang W., Boureau B., et al. Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood 2004, 103:67-72.
27. Lee W., Lockhart A.C., Kim R.B., et al. Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist 2005, 10:104-111.
28. Tuchman M., Stoeckeler J.S., Kiang D.T., et al. Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N Engl J Med 1985, 313:245-249.
29. Ciccolini J., Gross E., Dahan L., et al. Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope?. Clin Colorectal Cancer 2010, 9:224-228.
30. van der Meel R., Gallagher W.M., Oliveira S., et al. Recent advances in molecular imaging biomarkers in cancer: application of bench to bedside technologies. Drug Discov Today 2010, 15:102-114.
31. Choi H., Charnsangavej C., Faria S.C., et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007, 25:1753-1759.
32. Figueiras R.G., Padhani A.R., Goh V.J., et al. Novel oncologic drugs: what they do and how they affect images. Radiographics 2011, 31:2059-2091.
33. Prows C.A. Clinical aspects of genomics: an update. Online J Issues Nurs 2008, 13. Manuscript 2. Available at:. http://nursingworld.org/MainMenuCategories/ANAMarketplace/ANAPeriodicals/OJIN/TableofContents/vol132008/No1Jan08/ClinicalAspectsofGenomics.aspx.
34. Calzone K.A., Cashion A., Feetham S., et al. Nurses transforming health care using genetics and genomics. Nurs Outlook 2010, 58:26-35.
35. Junglen L., Pestka E., Clawson M., et al. Incorporating genetics and genomics into nursing practice: a demonstration. Online J Issues Nurs 2008, 13(3). Available at:. http://www.nursingworld.org/MainMenuCategories/ANAMarketplace/ANAPeriodicals/OJIN/TableofContents/vol132008/No3Sept08/ArticlePreviousTopic/IncorporatingGeneticsandGenomicsintoPractice.aspx.
36. Eggert J. The biology of cancer: what do oncology nurses really need to know. Semin Oncol Nurs 2011, 27:3-12.
37. Jenkins J. Essential genetic and genomic nursing competencies for the oncology nurse. Semin Oncol Nurs 2011, 27:64-71.